Supernus Pharmaceuticals (SUPN) FY 2025 Conference September 04, 2025 08:45 AM ET Company ParticipantsJaison Ellis - MD - Healthcare Investment BankingJack Khattar - CEO, President & DirectorJaison EllisGreat. Well, thank you all for coming. Welcome to the Supernus Pharmaceuticals fireside chat, the Wells Fargo Healthcare Conference. My name is Jason Ellis, and I'm pleased to have with me Jack Qatar, CEO of Supernus. Thank you, and good morning.Jack, do want to get started with just kind of an overview of t ...

Core Insights - Axsome Therapeutics is hosting its Frontiers in Brain Health R&D Day to showcase its CNS pipeline targeting various psychiatric and neurological conditions [1][2] - The event features presentations from six expert clinicians discussing clinical data from the company's pipeline programs [2] - Axsome Therapeutics focuses on developing differentiated products with novel mechanisms of action to improve patient outcomes in CNS disorders [4][5] Company Overview - Axsome Therapeutics is a biopharmaceutical company specializing in the treatment of central nervous system (CNS) conditions [4] - The company has FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine [5] - Axsome's pipeline addresses serious neurological and psychiatric conditions affecting over 150 million people in the United States [5] Event Details - The R&D Day is intended for institutional investors and sell-side analysts, with a live webcast available for broader access [3] - Presentations will cover conditions such as Alzheimer's disease, fibromyalgia, ADHD, and narcolepsy, with insights from leading experts in the field [2][4]

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today. For ...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline. At the event, physician key opinion leaders will discuss the company's current indications in ne ...

Core Insights - Axsome Therapeutics, Inc. is presenting seven studies at the SLEEP 2025 conference, focusing on AXS-12 and solriamfetol, which are aimed at treating central nervous system disorders [1] Group 1: AXS-12 Presentations - AXS-12 is being evaluated in a Phase 3 open-label extension and randomized-withdrawal trial for narcolepsy, with topline results presented by Dr. Richard Bogan [2] - The impact of AXS-12 on symptom severity and functional impairment in narcolepsy is being discussed, with results from the Phase 3 SYMPHONY trial presented by Dr. Michael Thorpy [2] - A subgroup analysis from the CRESCENDO survey highlights residual symptom burden in patients with narcolepsy who are satisfied with treatment, also presented by Dr. Michael Thorpy [2] Group 2: Solriamfetol Presentations - The effects of solriamfetol on neuropsychological outcomes in patients with obstructive sleep apnea are being presented in the real-world SURWEY study by Dr. Yaroslav Winter [3] - Real-world usage of solriamfetol for excessive daytime sleepiness in patients with obstructive sleep apnea in the U.S. is being discussed, led by Dr. Yang Zhao [3] Group 3: Product Information - AXS-12 (reboxetine) is a selective norepinephrine reuptake inhibitor under development for narcolepsy, with FDA Orphan Drug Designation granted [4][5] - Solriamfetol is a dopamine and norepinephrine reuptake inhibitor being developed for multiple conditions, including ADHD and excessive sleepiness associated with shift work disorder [6] Group 4: Company Overview - Axsome Therapeutics is focused on developing innovative treatments for CNS conditions, with a portfolio that includes FDA-approved therapies for major depressive disorder and excessive daytime sleepiness [7]